Lisa Anne Stuart
During her 30 year career, Ms. Stuart has taken on roles of increasing responsibility in production, sales, marketing, and corporate and business development. These include roles in Senior Management within the Financial Post, which led her to launch the website for the National Post, and subsequently by Yahoo! where she increased revenue and enhanced their online presence.
In the past ten years, Ms. Stuart was introduced to stable isotopes while working in the sales of deuterated compounds. Ms. Stuart brings with her an international perspective having lived in Japan, Switzerland, The United States & Canada. She has held international business roles that have taken her from Asia to Russia to Europe to Africa as well as across North and South America.
In 2017, Ms. Stuart became the Managing Director of deutraMed. Ms. Stuart holds a degree in psychology from Western University.
She meets the global demand for deuterated ingredients by overseeing custom solution design and key customer relations, and leading a dynamic team to drive company culture and vision towards bottom line success.
You may have seen Ms. Stuart bringing forward her passion for innovative deuterium solutions at industry conferences such as DCAT, DCAT Sharp Sourcing, SNMMI, AAPS, CPhi, Contract Pharma, and Informex.
Dr. Joseph P. Porwoll
Chairman of the board
Dr. Joseph P. Porwoll has over 30 years experience in the manufacturing of high-quality deuterated compounds/ingredients.
As the former President of Aldrich and VP of Supply Chain of Sigma Aldrich, his knowledge of customer requirements, products, and technical isotopic expertise is world class. In addition to the management responsibilities Dr. Porwoll held while at Aldrich and Sigma Aldrich, he has developed, manufactured and managed various stable isotope production systems including those with deuterium.
In 2017, Dr. Joseph P. Porwoll joined deutraMed as a Senior Technical Advisor. Dr. Porwoll holds a Ph.D. in Bio-Organic Chemistry from the University of Minnesota, Minneapolis.
Dr. Pavel Gris
Product Development and Chief Scientist
Dr. Gris joined deutraMed in 2018 and leads deutraMed’s scientific and analytic activities to develop and manufacture deuterated precursors for the pharmaceutical industry as well as deuterated intermediates for the electronics industry. In addition, Dr Gris studies efficient and innovative ways of synthesizing deuterated intermediates and precursors. He is an active member of our deuterium CMO team.
Dr. Gris joined deutraMed after a career in academia where he obtained extensive experience in a broad range of sciences, clinical research, and university level teaching at Western University, Concordia University, McGill University and University of North Carolina at Chapel Hill.
Dr Gris has a PhD in molecular neurosciences and bioinformatics from the Department of Physiology and Pharmacology at Western University, London, Canada. He has also completed two consecutive post-doctoral appointments at the University of North Carolina in Chapel Hill and McGill University in Montreal. Dr Gris is a member of the Royal Society of Chemistry.
deutraMed’s forward-thinking company culture of learning and discovery draws world-leading talent and empowers our team to innovate, perform, and stretch boundaries. Our entrepreneurial spirit and dedication to innovation and excellence drives everything we do at deutraMed. Through the passionate support of our employees and leading in-house expertise, we deliver deuterium innovations that foster a healthier and connected world.
Join Our Team
deutraMed is a fast-growing company and is constantly looking for top talent to join our team. We are always interested in learning of driven individuals who are interested in working with us to create a healthier and more connected world. If you believe your future lies in deuterium and it’s positive impact on the world, reach out to us.